SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 32.01-1.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dana Breite who wrote (167)2/13/1998 4:07:00 PM
From: Doug  Read Replies (1) of 340
 
If you see my earlier post in Nov, I questioned the projections for
Q4. TEVA has stated that expected income before adjustments will now be 30-34c for a rev of $290-292m which is a record. There was a window of opportunity for Copazone but only 50% of Sales forecast actually materialized that too with higher marketing costs. Now that there are other drugs on the market, it is unlikely that there will be a breakout in sales.
The rev for the next Q is going to be close to last Q. The margins of all Generics are being squeezed . Because of that, I foresee TEVA
also under pressure. I am therefore not comfortable with projections
which exceed 10% of the current numbers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News